This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kawamura, H. Articles by Claesson-Welsh, L. Search for Related Content PubMed PubMed Citation Articles by Kawamura, H. Articles by Claesson-Welsh, L.

Vascular Endothelial Growth Factor (VEGF)-A165b Is a Weak In vitro Agonist for VEGF Receptor-2 Due to Lack of Coreceptor Binding and Deficient Regulation of Kinase Activity

¹ Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; and ² Microvascular Research Laboratories, Bristol Heart Institute, Department of Physiology and Pharmacology, School of Veterinary Sciences, University of Bristol, Bristol, United Kingdom

Requests for reprints: Lena Claesson-Welsh, Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Dag Hammarskjöldsv. 20, 751 85 Uppsala, Sweden. Phone: 46-184714363; Fax: 46-18558931; E-mail: Lena.Welsh{at}genpat.uu.se.

Key Words: VEGF-A165b • VEGF receptor-2 • signal transduction • tyrosine phosphorylation • kinase regulation

Vascular endothelial growth factor (VEGF)-A165b is a COOH-terminal splice variant of VEGF-A that has been implicated in negative regulation of angiogenesis. We compared the properties of VEGF-A165b with those of VEGF-A121, VEGF-A145, and VEGF-A165. Induction of tyrosine phosphorylation sites in VEGFR-2 differed between the VEGF ligands as determined by tryptic phosphopeptide mapping and by use of phosphosite-specific antibodies. VEGF-A165b was considerably poorer in inducing phosphorylation of the positive regulatory site Y1052 in VEGFR-2. Whereas this did not affect activation of VEGFR-2 in vitro, we show that VEGF-A165b failed to induce vasculogenesis and sprouting angiogenesis in differentiating embryonic stem cells and vascularization of s.c. Matrigel plugs. In addition, the ability of the different VEGF ligands to induce angiogenesis correlated with their abilities to bind the VEGF coreceptor neuropilin 1 (NRP1). Our data indicate that loss of VEGFR-2/NRP1 complex formation and Y1052 phosphorylation contribute to the lack of angiogenic properties of VEGF-A165b. [Cancer Res 2008;68(12):4683–92]

This article has been cited by other articles:

				E. Mattila, K. Auvinen, M. Salmi, and J. Ivaska The protein tyrosine phosphatase TCPTP controls VEGFR2 signalling J. Cell Sci., November 1, 2008; 121(21): 3570 - 3580. [Abstract] [Full Text] [PDF]